Detalhe da pesquisa
1.
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.
Support Care Cancer
; 30(7): 6135-6144, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35426046
2.
A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
Support Care Cancer
; 30(10): 7913-7922, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35732748
3.
Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005-2017.
J Oncol Pharm Pract
; 27(1): 128-142, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32326872
4.
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.
Br J Haematol
; 187(4): 447-458, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31388996
5.
Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Support Care Cancer
; 27(4): 1449-1457, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30259136
6.
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Hematol Oncol
; 36(2): 463-470, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29446103
7.
Chemotherapy treatment patterns and neutropenia management in gastric cancer.
Gastric Cancer
; 18(2): 360-7, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24792482
8.
Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison.
Leuk Lymphoma
; 63(8): 1887-1896, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35289710
9.
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR.
Leukemia
; 35(6): 1732-1744, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33067574
10.
Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review.
BMJ Open
; 10(7): e034209, 2020 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32665382
11.
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials.
Leuk Lymphoma
; 61(1): 37-46, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31640435
12.
Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology.
Pharmacoeconomics
; 37(5): 727-737, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30610657
13.
Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting.
Oncol Ther
; 7(2): 141-157, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32699987
14.
Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS).
Hemasphere
; 2(4): e45, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31723779
15.
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
J Med Econ
; 21(5): 450-467, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29278014
16.
Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Clin Lymphoma Myeloma Leuk
; 18(6): e219-e240, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29793653
17.
G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Med Oncol
; 33(12): 139, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27822615
18.
Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
Med Oncol
; 32(10): 236, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26315712
19.
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.
J Cancer Res Clin Oncol
; 138(1): 65-72, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21960318